Melanóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

3285 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F32

  Investigating the mechanisms of KLRG1-mediated immune suppression in regulatory T cells

  Brown University· Providence, Egyesült Államok· 79 780 USD awarded in fiscal year 2026· until 2029. okt.

• ALLCDC NCCDPHP · R43

  Parents and Schools for Sun Safety (PASS): A Family-Based Skin Cancer Prevention Program for Schools

  Klein Buendel, Inc.· Lakewood, Egyesült Államok· 311 239 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NCI · R21

  Optimizing TIL Harvest Site and Patient Selection with CD8-PET Imaging

  University of Tx Md Anderson Can Ctr· Houston, Egyesült Államok· 421 685 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAMS · R00

  Investigating the Role of Cancer-Associated Fibroblasts in Immunodetection of Mycosis Fungoides

  Beckman Research Institute/City of Hope· Duarte, Egyesült Államok· 249 000 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NIA · R43

  RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biology

  Ora Biomedical, Inc.· Tukwila, Egyesült Államok· 299 783 USD awarded in fiscal year 2026· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Lipopolysaccharide Lipid A Profiling to Guide Microbiome-Supported Immunotherapy in Melanoma (LPS-Pro)

  Universita Degli Studi di Napoli Federico Ii· Napoli, Olaszország· EU contribution 150 000 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spanyolország· EU contribution 150 000 EUR· until 2028. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Decoding Early-Life UVA and Skincare Additive Interactions Driving Melanoma Risk and Progression in Young Adults (PhotoMel)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 5 709 196 EUR· until 2030. aug.· 5 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SPAtial single-CEll omics research training for MELanoma precision medicine (SPACE-MEL)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 4 565 428 EUR· until 2030. aug.· 9 countries

10 of 1011 running projects, newest first. Listed amounts together: 571,0 M USD + 83,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 10.

  “\<75% participation”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  NCT04318717· Washington University School of Medicine· Frissítve: 2026. nov. 6.

  “protocol amendment”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

  NCT07803562· University of California, San Diego· Frissítve: 2026. nov. 6.

  “Lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

  NCT06673095· OHSU Knight Cancer Institute· Frissítve: 2026. okt. 20.

  “Pending coordinating center transition”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Frissítve: 2026. okt. 20.

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases

  NCT05669352· Mayo Clinic· Frissítve: 2026. okt. 20.

  “transition to new institution”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

  NCT06365619· University of Utah· Frissítve: 2026. okt. 19.

  “Low Accrual”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

  NCT04866810· National Cancer Institute (NCI)· Frissítve: 2026. okt. 19.

  “On hold pending planned interim analysis.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Agenus Inc.· Frissítve: 2026. okt. 19.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Frissítve: 2026. okt. 16.

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Forrás

• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

  NCT03816332· National Cancer Institute (NCI)· Forrás

• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

  NCT04557956· National Cancer Institute (NCI)· Forrás

• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  NCT02332668· Merck Sharp & Dohme LLC· Forrás

• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

  NCT00923026· National Cancer Institute (NCI)· Forrás

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Forrás

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Forrás

• Harvesting Cells for Experimental Cancer Treatments

  NCT00068003· National Cancer Institute (NCI)· Forrás

• Evaluation for NCI Surgery Branch Clinical Research Protocols

  NCT00001823· National Cancer Institute (NCI)· Forrás

• Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  NCT05111574· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 107
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Generation of Functional Gene Knockout Melanoma Cell Lines by CRISPR-Cas9 Gene Editing.

  Methods Mol Biol, 2027. jan.

• Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming.

  J Am Chem Soc, 2026. nov.

• Dual-vector nanoengineered mRNA-CRISPR delivery systems for precision gene therapy in choroidal melanoma.

  Nanomedicine (Lond), 2026. okt.

• CRISPR-Cas9 screen identifies eIF4G2 as a regulator of CD8+ T cell dysfunction.

  J Immunol, 2026. okt.

• CD73 disruption with tumor-specific CRISPR/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy.

  Nat Commun, 2026. szept.

  Meng Zheng

• CRISPR screens reveal MCT1-driven metabolic escape from SMAD3 inhibition as a therapeutic vulnerability.

  Mol Cancer, 2026. aug.

• MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening.

  Genes (Basel), 2026. júl.

• Effective gene editing of melanoma by delivery of Cas9 mRNA with highly branched poly(β-amino ester).

  J Mater Chem B, 2026. jún.

• In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis.

  Oncogene, 2026. jún.

• Molecular Landscape and Advanced Diagnostic Technologies for BRAF Mutations in Cancer: From Quantitative PCR and ddPCR to CRISPR-Based Platforms.

  Clin Chim Acta, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.